Go to content
Galapagos NV

Galapagos NV

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 07 dec 2015 - 22:46
Statutaire naam Galapagos NV
Titel Filgotinib meets primary endpoint in phase 2 study in patients with moderate to severe Crohn's disease
Bericht • First JAK-inhibitor to show efficacy in Crohn's disease • 48% clinical remission rate, statistically significant versus placebo after 10 weeks induction therapy • Significant improvements in clinical response and IBDQ quality of life • Filgotinib safety profile similar to that previously observed Webcast presentation of the results to be held tomorrow 8 December, 16.00 CET/10 AM EDT/7 AM PDT, +1646 254 3373 access code 4725658 more call number info further down Mechelen, Belgium; 7 December 2015 - Galapagos NV (Euronext & NASDAQ: GLPG) announced today that 200 mg filgotinib is shown to be effective and safe as once-daily, oral induction treatment in moderate to severe Crohn's disease, based on the FITZROY phase 2 study at the 10-week interim analysis. The study achieved the primary endpoint of clinical remission: the percentage of patients achieving a CDAI score lower than 150 was significantly higher in patients treated with filgotinib versus patients receiving placebo. Filgotinib was shown to be well tolerated in the FITZROY study, strengthening its favorable safety profile.